Cell Line Development
Curia offers advanced methods to rapidly move programs from DNA to RCB utilizing methods to ensure clonality and maximize titer. The TunaCHO℠ platform for transient production and the CHO-GSN℠ platform for stable cell line expression use the same CHO-K1 parental so products from the different platforms have similar activity & post-translational modification (PTM) profiles.
Developed from the same CHO-K1 parental cell line as our TunaCHOSM transient production system, Curia offers the CHO-GSNSM stable cell line expression platform for the production of the proteins and antibodies.
The CHO-GSNSM platform provides a glutamine synthetase (GS) knockout cell line for the generation of a research cell bank (RCB) and future use as a manufacturing cell line for commercial products.
Curia’s CHO-GSNSM CHO-K1 GS knockout for stable cell line generation is:
- Well characterized, providing the ability to enable a 12-month construct to clinic platform
- Compatible with chemically defined commercial media
- Robustly tested for bioreactor production and shear force tolerance
- Used in 100+ pre-clinical programs and clinical trials across various protein modalities (mAb, bi-specific, fc-fusion, enzyme)
- Cost effective with competitive with flexible licensing options compared to other premium CHO production systems
Curia’s Technological Approach
- Electroporation to ensure efficient delivery of desired genes of interest to the cellular fabric
- Single cell plating to isolate multiple high expressors
- Cellular imaging to monitor proliferation of a consistent monoclonal cell line
Features
- Stable transfections to CHO-GSNSM and CHOZN® cell lines
- Proven stability >60 generations
- Single cell cloning and monitoring for production of stable research cell lines
- Documented progression of research to master cell bank implementation
